logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Anuh Pharma Ltd

Anuh Pharma

Small Cap•295 Employees•IPO 1995
Current Price
₹77.61
0.27 (0.35%)Updated
NSE :ANUHPHR
BSE :506260
Sector :Pharmaceuticals
Today's Range
₹77.21
₹77.61
union icon
₹77.97
52 Week Range
52W Low₹69.27
52W High₹229.80
₹77.61
union icon
Downside12.04%
Upside196.10%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹818.83 Cr
Market Cap
Total market value of company
P/E Ratio
20.97
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
2.56
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹3.86
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
6.15%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
17.20%
ROCE
Return on Capital Employed. >15% is good
Net Margin
5.30%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
10.60%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
16.60%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
35.20%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
-12.70%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.03
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹32.53
Book Value
Net asset value per share
Dividend Yield
1.85%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
71.80%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Promoter holding is robust at 71.8%, indicating strong management confidence.
  • •Quarterly sales growth of 35.20% demonstrates strong top-line performance.

Weaknesses

5 points
  • •Significant quarterly profit decline of -12.70% raises margin concerns.
  • •Current stock price 89.60 is substantially below its 52-week high 245.70.

Opportunities

5 points
  • •Leverage high Pharmaceuticals sector P/E (79.78) for future expansion.
  • •Invest in R&D for new drug development or niche therapeutic areas.

Threats

4 points
  • •Highly competitive pharmaceutical sector with larger, established peers.
  • •Strict regulatory changes in drug policies or pricing could impact operations.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹79.50+₹1.89+2.44%
R3₹78.74+₹1.13+1.46%
R2₹78.36+₹0.75+0.96%
R1₹77.98+₹0.37+0.48%
PIVOT₹77.60-0.01-0.02%
CURRENT₹77.61--
S1₹75.70-₹1.91-2.46%
S2₹76.46-₹1.15-1.48%
S3₹76.84-₹0.77-1.00%
S4₹77.22-₹0.39-0.50%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.17L
(06 Mar 2026)
-63.5% vs avg
Delivery %
69.1%
(06 Mar 2026)
+5.1% vs avg
Avg Volume (20D)
0.46L
(06 Feb - 06 Mar)
20-day average
Avg Delivery %
63.9%
(06 Feb - 06 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Wanbury Ltd
1197.00 %
Highest Dividend Yield
Kopran Ltd
2.26 %

Peer Comparison

Company Name
AHCL
KILITCH
Kilitch Drugs (India) Ltd
KOPRAN
Kopran Ltd
LINCOLN
Lincoln Pharmaceuticals Ltd
NGLFINE
NGL Fine Chem Ltd
SAKAR
Sakar Healthcare Ltd
SIGACHI
Sigachi Industries Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
THEMISMED
Themis Medicare Ltd
VENUSREM
Venus Remedies Ltd
WANBURY
Wanbury Ltd

About

ANUHPHR

Anuh Pharma Ltd

Anuh Pharma Limited is an Indian pharmaceutical company primarily focused on the manufacturing and sale of bulk drugs and chemicals. Its core business revolves around the production of Active Pharmaceutical Ingredients (APIs), which are the fundamental components used in the formulation of various medicines. This makes Anuh Pharma a key player in the pharmaceutical supply chain, rather than directly selling finished medications to consumers.

The company's API portfolio is quite diverse, encompassing a wide range of therapeutic areas. Key product categories include macrolides (a class of antibiotics), anti-tuberculosis drugs, anti-malarial medications, and various antibacterial agents. Beyond infectious disease treatments, Anuh Pharma also produces APIs for cardiovascular health (anti-hypertension drugs) and respiratory conditions (expectorants). Further broadening their product line, they offer quinolones (another class of antibiotics) and essential intermediates used in the synthesis of other APIs. This demonstrates a strategic approach to supplying raw materials for a significant portion of the pharmaceutical market.

In addition to its extensive range of antibiotics and cardiovascular APIs, Anuh Pharma also manufactures corticosteroids. These versatile drugs have a variety of applications, including anti-inflammatory, immunosuppressant, anti-pruritic (anti-itch), anti-mitotic (cell division inhibiting), and anti-histamine properties. This further diversifies their product offering and caters to a broader range of pharmaceutical needs. The production of corticosteroids showcases Anuh Pharma's capability in complex chemical synthesis and manufacturing processes.

An important aspect of Anuh Pharma's business model is its export operations. The company actively engages in international trade, selling its APIs to pharmaceutical companies and manufacturers in various countries. This signifies a significant presence in the global pharmaceutical supply chain and contributes to the company's revenue generation. The international market access enhances its reach and potential for growth.

Established in 1960 and headquartered in Mumbai, Anuh Pharma has a long history of operation within the Indian pharmaceutical industry. Its longevity and consistent production of a broad array of APIs illustrate a commitment to quality and sustained relevance in a competitive market. The company’s continued success likely hinges on its ability to adapt to evolving market demands and technological advancements in pharmaceutical manufacturing.

COMPANY FACTS - ANUHPHR

Registered Address

3-A Shivsasgar Estate, North Wing, Dr. Annie Besant Road, Dr.Annie Basent Road, Worli

Mumbai

MAHARASHTRA

IN

Tel: 912266227575

Website:https://www.anuhpharma.com/

Investor Relations:http://www.anuhpharma.com/Investor.html
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 295

IPO Date: 19/04/1995

MANAGEMENT - ANUHPHR

Mr. Arun Todarwal

Non-Executive Chairman of the Board

Shri. Bipin Shah

Non-Executive Vice Chairman of the Board

Mr. Darshan Rampariya

Chief Financial Officer

Mr. Manan Vadhan

Compliance Officer, Company Secretary

Mr. Ritesh Bipin Shah

Joint Managing Director, Executive Director

Mr. Vivek Shah

Joint Managing Director, Executive Director

Shri. Bharat Shah

Non-Executive Director

Mr. Gaurav Shah

Additional Non-Executive Director

Mr. Ketan Shah

Non-Executive Director

Mr. Samir Shah

Non-Executive Director

Dr. Mita Dixit

Additional Non-Executive Independent Woman Director

Mr. Harmanbhai Patel

Non-Executive Independent Director

Investor Questions Answered

Anuh Pharma Ltd (ANUHPHR) Stock FAQs

Get answers to the most common questions about Anuh Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Anuh Pharma Ltd (ANUHPHR) is ₹77.61. Today, the stock has gained by ₹0.27 (0.35%), trading in a range of ₹77.21 to ₹77.97. The stock opened at ₹77.76 with a trading volume of 16,797 shares.
Anuh Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹818.83 crores, P/E ratio of 20.97, ROE of 6.15%, and ROCE of 17.20%. The dividend yield stands at 1.85%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Anuh Pharma Ltd (ANUHPHR) is ₹229.8, while the 52-week low is ₹69.27. Currently trading at ₹77.61, the stock is 5.2% away from its 52-week low and 66.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Anuh Pharma Ltd stock at ₹77.61 depends on multiple factors. The stock is currently trading with a P/E ratio of 20.97 and P/B ratio of N/A. Today's performance shows a gain of 0.35%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Anuh Pharma Ltd offers a dividend yield of 1.85%, which means for every ₹100 invested at the current price of ₹77.61, you can expect to receive approximately ₹1.85 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Anuh Pharma Ltd's key financial metrics include: P/E Ratio: 20.97, P/B Ratio: N/A, ROE: 6.15%, ROCE: 17.20%, Dividend Yield: 1.85%, EPS: ₹3.86, Book Value: ₹32.53, Debt-to-Equity: 0.03, and Current Ratio: N/A. The company's market cap stands at ₹818.83 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Anuh Pharma Ltd stock opened at ₹77.76 and is currently trading at ₹77.61, showing a gain of ₹0.27 (0.35%). The intraday high is ₹77.97 and low is ₹77.21. The trading volume stands at 16,797 shares, indicating moderate market participation today.
Anuh Pharma Ltd has a Price-to-Earnings (P/E) ratio of 20.97, which means investors are willing to pay ₹20.97 for every ₹1 of earnings. With an EPS of ₹3.86, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Anuh Pharma Ltd has a market capitalization of ₹818.83 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹77.61) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Anuh Pharma Ltd has a book value of ₹32.53 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹77.61, which is 138.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Anuh Pharma Ltd has a Return on Equity (ROE) of 6.15% and Return on Capital Employed (ROCE) of 17.20%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Anuh Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Anuh Pharma Ltd has a debt-to-equity ratio of 0.03, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Anuh Pharma Ltd has an Earnings Per Share (EPS) of ₹3.86, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹77.61 and P/E ratio of 20.97, investors are paying 20.97 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Anuh Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Anuh Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Anuh Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (20.97), ROE (6.15%), debt-to-equity (0.03), and growth rates. 2) Technical Analysis - Check 52-week range (₹69.27 - ₹229.80), moving averages, and chart patterns. 3) Valuation - Compare current price (₹77.61) with book value (₹32.53) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Anuh Pharma Ltd share is ₹5.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹77.61 is 1452x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Anuh Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹69.27 - ₹229.80). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.03 indicates leverage. 4) Liquidity Risk - Based on trading volume of 16,797 shares. 5) Valuation Risk - P/E of 20.97 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Anuh Pharma Ltd operates in the industry with key metrics: P/E ratio of 20.97, ROE of 6.15%, market cap of ₹818.83 crores, and dividend yield of 1.85%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.03), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Anuh Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹77.61, with a 52-week range of ₹69.27 to ₹229.80. Based on fundamentals like P/E (20.97), ROE (6.15%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Anuh Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹77.61. 2) Fundamental Deterioration - Declining ROE (currently 6.15%), increasing debt (D/E: 0.03), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Anuh Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 1.85%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.